Background: YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was conducted to determine the activity of YM155 in patients with castrationresistant prostate cancer (CRPC) who received prior taxane therapy. Results:Thirty-five patients were enrolled. Two of 32 (6.2%) assessable patients had a PSA response and 2 additional patients had PSA decrements >50% but not confirmed. One of 16 (6.2%) patients also had a partial response per RECIST V1. Median PFS and OS were 3.1 and 11.2 months, respectively. The most common adverse events were fatigue (63%), nausea (40%), anorexia (31%), constipation (31%), fever (26%) and vomiting (26%).
introduction
Survivin is a member of the inhibitor of apoptosis family of proteins and a critical regulatory protein inhibiting malignant cell apoptosis acting at the level of the microtubule as well as the mitochondria [1] . Survivin expression is increased in most solid tumors as well as hematologic malignancies but is undetectable in most normal adult tissues. Survivin expression appears to be an early and continuing event in prostate carcinogenesis. Survivin has been detected in prostate intraepithelial neoplasia, in both castrate-sensitive and -resistant prostate cancer and has been associated with a poor prognosis with an increased rate of recurrence after local therapy [1] [2] [3] . Furthermore, preclinical studies show that survivin mediates, at least in part, the progression to castrateresistant state as well as the resistance to cell kill induced by many chemotherapy agents [2, 4, 5] .
YM155 is a small-molecule suppressor of the antiapoptosis protein survivin. YM155 mechanism of action has been shown to be mediated through a 2-kb promoter region of survivin gene. The exact molecular mechanism of action by which YM155 down-regulates survivin gene expression at the messenger RNA (mRNA) and subsequently protein level is not fully known to date. In preclinical models including prostate cancer cell lines, YM155 treatment resulted in both dosedependent and time-dependent reduction in survivin mRNA and protein expression, increased apoptosis and tumor cell kill. In human prostate tumor (PC-3) xenograft studies, singleagent YM155 induced tumor regressions and when combined with docetaxel had enhanced activity in Calu-6 human tumorbearing animals [6] .
A phase I study of YM155 carried out in patients with advanced solid tumors determined a maximum tolerated dose of 4.8 mg/m 2 /day for 168 h by continuous i.v. infusion (CIVI). Two patients with castration-resistant prostate cancer (CRPC) who had received prior docetaxel treatment had prostatespecific antigen (PSA) responses, and an additional three patients with non-Hodgkin's lymphoma (NHL) had durable partial responses (PRs) including one patient with a complete response. These responders followed two distinct time courses for response that included a fast response seen with the initial cycles of therapy in two subjects (one NHL, one CRPC) as well as slow response at or beyond six cycles of therapy (two NHL, one CRPC patient).
Based upon the role that survivin has in mediating tumor cell survival and in prostate cancer as well as other malignancies, and preliminary evidence of antitumor activity in docetaxeltreated CRPC, a phase II study of YM155 was initiated in patients with CRPC who had received at least one prior taxane regimen. The objectives of this study were to determine the antitumor activity of YM155 in patients with CRPC (i) during the first six cycles of therapy; (ii) during all cycles of therapy and (iii) in patients with bidimensionally measurable disease.
patients and methods

study population
Eligible male patients had pathologically confirmed prostate cancer that was resistant to standard hormone therapy and had received one prior taxane-containing chemotherapy regimen. Patients were allowed to enroll if previous chemotherapies, including investigational therapies, and antiandrogen therapies were completed 4 weeks before YM155 administration. Initiation of bisphosphonates were not permitted during the study; however, patients were allowed to continue on bisphosphonates as long as the medication was initiated at least 4 weeks before the first dose of YM155. In addition, patients met the following criteria including age ‡18 years; life expectancy ‡12 weeks; an Eastern Cooperative Oncology Group performance status of zero to two; baseline PSA of >5 ng/ml with a rising PSA level on at least two prior occasions at least 1 week apart; castration level of serum testosterone (£50 ng/ml); demonstration of a new evaluable lesion on imaging or progression of at least a 20% increase in objective tumor measurements since last treatment; off prior nonsteroidal antiandrogen for 4 weeks (6 weeks for prior bicalutimide or nilutamide); absolute neutrophil count ‡1500/ll; platelets ‡100 000/ll; creatinine £1.5 · upper limit of normal (ULN) or calculated creatinine clearance ‡60 ml/min; bilirubin £ 1.5 · ULN; aspartate serum transaminase (AST), alanine serum transaminase (ALT) £2.5 · ULN; absence of brain metastases and no coexisting severe medical conditions.
study design
This was a nonrandomized study evaluating YM155 administered as a CIVI over 168 h every 21 days (168 h on treatment; 14 days off treatment) in patients with CRPC. The primary end point was PSA response utilizing the Prostate-Specific Antigen Working Group (PWG1) 1999 criteria. Secondary end points included objective tumor response utilizing RECIST version1, progression-free survival (PFS), overall survival (OS) and safety. The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines, the Declaration of Helsinki and applicable local regulatory requirements and laws. The institutional review board or independent ethics committee of each participating center approved the study protocol and all patients provided informed consent.
study treatments
YM155 was administered via an indwelling i.v. catheter by CIVI over 168 h via a portable infusion pump. In all cycles, subjects were treated in the ambulatory setting and the infusion was repeated every 21 days. Toxicity was graded according to the National Cancer Institute-Common Toxicity Criteria, Version 3.
YM155 was supplied in vials containing 30 mg YM155 in 3 ml lactic acid-based buffer (pH 3.6) by Astellas Pharma US, Inc. (Deerfield, IL) and Astellas Pharma Europe B.V. (Leiderdorp, The Netherlands). Each admixture was prepared in a controlled light and temperature environment with 5% dextrose or 0.9% normal saline as a diluent.
assessments
A complete history, physical examination and routine laboratory studies including a complete blood count, white blood count, chemistry including electrolytes, blood urea nitrogen, creatinine, uric acid, glucose, alkaline phosphatase, lactate dehydrogenase, ALT, AST, total bilirubin, calcium, total protein, albumin, cholesterol, triglycerides, creatine phosphokinase, urinalysis, electrocardiogram, relevant radiologic studies and PSA levels were carried out before treatment.
Blood sampling was carried out on all subjects during the first six cycles to determine a population pharmacokinetic profile. During cycle 1, blood samples were collected immediately before infusion and anytime on days 4 and 6 and then anytime between 5 min and 4 h before end of infusion (EOI), 5 min and 4 h after EOI and 6-24 h after EOI. During cycles 2-6, samples were collected anytime on day 4. Blood samples were centrifuged at 500 g for 10 min immediately after collection, and the plasma was stored frozen at 270°C until assayed. The assay for YM155 has been previously described [7] .
During the study, subjects with measurable disease at baseline had radiologic studies for disease status repeated after every other cycle. PSA was measured by a central laboratory and PSA response was defined as a 50% decrease without evidence of clinical or radiographic progression that was confirmed by a second PSA value at least 3 weeks apart. Subjects with measurable disease had response evaluation as defined by RECIST Version 1. Bone scans were obtained every three to six cycles depending upon the results at baseline, positive or negative, respectively.
statistical methods
A Simon two-stage 'minimax' model [8] was utilized to design the first two stages of this study. In the first stage, 13 assessable subjects were to be enrolled and at least one patient required a PSA response within the first six cycles in order to move to the second stage. In the second stage, an additional 14 patients were to be enrolled for a total of 27 patients. For sample size determination for these two stages, a = 0.05 and power = 80%. The response rate that would not justify further development in this patient population as single agent was sent at P 0 = 0.05 and a response rate that was deemed worth further evaluation was set at P 1 = 0.20. If at least four responses were observed in 27 patients, then an additional 33 patients were to be enrolled to further characterize the efficacy and safety of this regimen in this patient population.
results patient population and disposition
Thirty-five patients with CRPC were enrolled. One of 13 patients enrolled in stage 1 had a PSA response that allowed for enrollment into stage 2. One additional patient in stage 2 had a PSA response. Eight patients were enrolled beyond the stage 2 requirements of 27 due to the timing of the patients' consents and screening process in relation to the enrollment of the 27th patient. The study was terminated after stage 2 due to lack of activity. The pertinent characteristics of the patients are displayed in Table 1 . Thirty-two patients were assessable for response assessments (3 patients discontinued study before receiving two cycles), 16 patients had measurable disease at baseline and were assessable for tumor response and all patients were included in the safety analysis. Six patients (17%) completed the study, 26 patients (74%) discontinued the study due to disease progression, 2 patients withdrew due to adverse events (AEs; intracranial hemorrhage, DIC) and 1 patient withdrew consent.
treatment summary
A total of 128 cycles of YM155 were administered. The median number of cycles administered per patient was 3 (range 1 to 16+). One subject required dose reduction to 3.6 mg/m 2 /day for dose-limiting toxicity of rising serum creatinine.
efficacy
Two of 32 (6%) assessable patients had a PSA response lasting 21 and 112 days, 2 additional patients had PSA decrements of >50% that were not confirmed, and 3 additional patients had lesser falls in PSA that did not meet the definition of response (Figure 1) . A PR was noted in 1 of 16 (6.2%) of the subjects with measurable disease. The one patient with both a PSA response and a PR responded at cycle 6. In addition, eight patients (25%) had stable disease (SD) after 6 cycles of therapy and two patients completed the protocol-mandated maximum of 10 cycles of therapy without evidence of progression. A waterfall plot depicts the results of PSA change (Figure 1 ) and duration on study (Figure 2) .
The median survival of the entire treated population (n = 35) was 11.2 months [95% confidence interval (CI) 7.57-24.5 months], and the median PFS was 3.1 months (95% CI 2.12-6.28 months).
safety
The most common ( ‡5%) AEs considered possibly or probably related to YM155 are presented in Table 2 . There were no AEs ‡grade 3 considered related to YM155 that occurred in more than one patient. However, the AEs that Table 3 . Eighteen subjects (51.4%) reported a total of 47 serious adverse events (SAEs). The most common SAEs were constipation, pyrexia, hyperglycemia, hypokalemia, back pain and bone pain. Five subjects had six SAEs considered related to YM155. A total of six patients died during the study, four during the treatment period or within 30 days after the last dose of YM155 and two during the follow-up period. Three patients died due to disease progression, one patient died due to pneumonia, another due to cardiopulmonary arrest and the last patient died due to intracranial hemorrhage. The intracranial hemorrhage was the only event considered possibly related to YM155. This 78-year-old patient died after the first cycle. His medical history was significant for hypertension and coronary artery disease and he was taking multiple medications for deep vein thrombosis prophylaxis at the time of death. pharmacokinetics Thirty-four subjects had population-based pharmacokinetic sampling. The median plasma concentrations at day 4, 6 and 8 (5 min before EOI) were 9.63, 9.17 and 9.50 ng/ml, respectively. The clearance was 44.01 l/h.
discussion
The failure of therapies to eradicate disseminated prostate cancer is a major unmet need. Castration remains the single most effective therapy in recurrent and advanced prostate cancer resulting in tumor cell apoptosis, marked PSA decrease, resolution of symptoms and improvement in evaluable disease for the majority of patients. None the less, the development of CRPC occurs almost universally and docetaxel-based chemotherapy for CRPC achieves a more modest rate of PSA reduction, symptom control and reduction in disease. Cabazitaxel was recently approved in the United States, based upon survival benefit (15.1 versus 12.7 months) reported from the phase III Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (TROPIC Study), for second-line Annals of Oncology original articles treatment of CRPC in men who have already been treated with docetaxel-based chemotherapy. However, the most common grade 3 or 4 toxicity for the cabazitaxel arm was neutropenia (81.7%) with rates of febrile neutropenia reported at 7.5% [9] . Although this is the first agent since docetaxel to show survival benefit in this setting, based upon the toxicity profile there remains room for improvement of therapies in this patient population. Survivin represents an important strategic target in human malignancies that is differentially expressed in malignancies compared with most normal adult tissues and has a critical role in abrogating apoptosis signaling at the late stage in the apoptotic pathways that regulate cell life/death decisions. As such, suppression of survivin may induce tumor regression in those malignancies that exist in a pro-apoptotic state but are restrained from undergoing apoptosis primarily by survivin expression alone. This study was designed to evaluate if YM155 would induce response (PSA, objective tumor) in castration-resistant docetaxel-pretreated prostate cancer patients.
In this study, there was a definite, albeit modest, singleagent response in taxane-pretreated patients, but a considerable proportion of SD was observed. This was not unexpected since survivin inhibits caspase activation via second mitochondrial apoptosis-induced channel sequestration for both the intrinsic and extrinsic apoptosis pathways. Therefore, only those tumor cells that were in a pro-apoptotic state and restrained from undergoing apoptosis by survivin expression would likely respond to single-agent therapy. In tumor cells that are not in a proapoptotic state that is restrained by survivin function, suppression of survivin may induce at best SD. Similarly, modest single-agent response rates (<10%) have been observed with other apoptosis pathway-targeting therapies including Bcl-2 inhibition in lymphoid malignancy patients. Furthermore, survivin expression is but one of a number of molecular abnormalities that abrogate apoptosis and redundant mechanisms may exist within the same tumors [10, 11] .
This study confirmed the tolerability of YM155 when administered at 4.8 mg/m 2 /day for 168 h as well as the attainment of plasma concentrations that induced responses in the phase I trial. Three subjects had a rise in serum creatinine, but only one subject required a dose reduction.
The greatest utility of survivin-targeting therapies will likely emerge when used in combination with cytotoxic, hormonal and targeted therapies, all of which have the potential to activate the apoptotic pathways and lead to mitochondrial depolarization. In preclinical studies, the combination of YM155 with docetaxel is synergistic in many models. Based upon this, a phase Ib study of YM155 in combination with docetaxel was initiated and recently completed. 
